These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19138309)

  • 1. Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report.
    Wild D; Eremenco S; Mear I; Martin M; Houchin C; Gawlicki M; Hareendran A; Wiklund I; Chong LY; von Maltzahn R; Cohen L; Molsen E
    Value Health; 2009 Jun; 12(4):430-40. PubMed ID: 19138309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
    Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
    Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translation and psychometric properties of the Persian version of self-management of type 1 diabetes for adolescents.
    Karahroudy FA; Shahboulaghi FM; Hosseini MA; Rassouli M; Biglarian A
    J Pediatr Endocrinol Metab; 2016 Jul; 29(7):761-7. PubMed ID: 27124671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of electronic systems to collect patient-reported outcome (PRO) data-recommendations for clinical trial teams: report of the ISPOR ePRO systems validation good research practices task force.
    Zbrozek A; Hebert J; Gogates G; Thorell R; Dell C; Molsen E; Craig G; Grice K; Kern S; Hines S
    Value Health; 2013 Jun; 16(4):480-9. PubMed ID: 23796281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
    Hoaglin DC; Hawkins N; Jansen JP; Scott DA; Itzler R; Cappelleri JC; Boersma C; Thompson D; Larholt KM; Diaz M; Barrett A
    Value Health; 2011 Jun; 14(4):429-37. PubMed ID: 21669367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force.
    Eremenco S; Coons SJ; Paty J; Coyne K; Bennett AV; McEntegart D;
    Value Health; 2014 Jul; 17(5):501-16. PubMed ID: 25128043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pragmatic approach ensuring accuracy in language translation in tuberculosis research.
    Rennie TW; Engova D; Bates I
    Res Social Adm Pharm; 2008 Dec; 4(4):417-21. PubMed ID: 19064247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.
    Cleeland CS; Sloan JA; Cella D; Chen C; Dueck AC; Janjan NA; Liepa AM; Mallick R; O'Mara A; Pearson JD; Torigoe Y; Wang XS; Williams LA; Woodruff JF;
    Cancer; 2013 Jan; 119(2):411-20. PubMed ID: 22930243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
    Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
    Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries.
    Two R; Verjee-Lorenz A; Clayson D; Dalal M; Grotzinger K; Younossi ZM
    Value Health; 2010; 13(1):128-31. PubMed ID: 19695006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linguistic validation of the DN4 for use in international studies.
    Van Seventer R; Vos C; Meerding W; Mear I; Le Gal M; Bouhassira D; Huygen FJ
    Eur J Pain; 2010 Jan; 14(1):58-63. PubMed ID: 19282208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.